| Dr Walter David Smith, MD | |
|
1940 Harrison Ave, Panama City, FL 32405-4542 | |
| (850) 763-0017 | |
| (850) 692-5862 |
| Full Name | Dr Walter David Smith |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 11 Years |
| Location | 1940 Harrison Ave, Panama City, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245664531 | NPI | - | NPPES |
| 07832520 | Medicaid | MS |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Bhc West Virginia Llc | 2860818499 | 6 |
News Archive
A stopgap bill to fund the government when the fiscal year ends Oct. 1 continues to be caught up in Republican efforts to defund, delay or derail the health law. Federal agencies have contingency plans in place.
It's the time of year when many of us celebrate the holidays with festive foods and drinks, including alcohol. No better time then to ask if it is true, as is widely held, that moderate consumption of alcohol is beneficial to health.
InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries and other neurotrauma conditions, today announced that the Company has received approval for its request filed with the U.S. Food and Drug Administration for Humanitarian Use Device designation for its biopolymer scaffolding product.
Johns Hopkins and other cancer researchers report that a very short course of a chemotherapy drug, called cyclophosphamide, not only can prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate such patients' need for the usual six months of immune suppression medicines commonly prescribed to prevent severe forms of this immune response.
Although two RNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates elicited similar, dose-dependent neutralizing antibody titers in both younger and older adults, a recent study by researchers from the U.S. and Germany has shown that BNT162b2 is associated with less systemic reactogenicity in elderly individuals – supporting its selection for further phase 2/3 clinical trials. The study is currently available on medRxiv* preprint server.
› Verified 3 days ago
| Entity Name | Summit Bhc West Virginia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801411905 PECOS PAC ID: 2860818499 Enrollment ID: O20200813001564 |
News Archive
A stopgap bill to fund the government when the fiscal year ends Oct. 1 continues to be caught up in Republican efforts to defund, delay or derail the health law. Federal agencies have contingency plans in place.
It's the time of year when many of us celebrate the holidays with festive foods and drinks, including alcohol. No better time then to ask if it is true, as is widely held, that moderate consumption of alcohol is beneficial to health.
InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries and other neurotrauma conditions, today announced that the Company has received approval for its request filed with the U.S. Food and Drug Administration for Humanitarian Use Device designation for its biopolymer scaffolding product.
Johns Hopkins and other cancer researchers report that a very short course of a chemotherapy drug, called cyclophosphamide, not only can prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate such patients' need for the usual six months of immune suppression medicines commonly prescribed to prevent severe forms of this immune response.
Although two RNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates elicited similar, dose-dependent neutralizing antibody titers in both younger and older adults, a recent study by researchers from the U.S. and Germany has shown that BNT162b2 is associated with less systemic reactogenicity in elderly individuals – supporting its selection for further phase 2/3 clinical trials. The study is currently available on medRxiv* preprint server.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Walter David Smith, MD 1940 Harrison Ave, Panama City, FL 32405-4542 Ph: (850) 763-0017 | Dr Walter David Smith, MD 1940 Harrison Ave, Panama City, FL 32405-4542 Ph: (850) 763-0017 |
News Archive
A stopgap bill to fund the government when the fiscal year ends Oct. 1 continues to be caught up in Republican efforts to defund, delay or derail the health law. Federal agencies have contingency plans in place.
It's the time of year when many of us celebrate the holidays with festive foods and drinks, including alcohol. No better time then to ask if it is true, as is widely held, that moderate consumption of alcohol is beneficial to health.
InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries and other neurotrauma conditions, today announced that the Company has received approval for its request filed with the U.S. Food and Drug Administration for Humanitarian Use Device designation for its biopolymer scaffolding product.
Johns Hopkins and other cancer researchers report that a very short course of a chemotherapy drug, called cyclophosphamide, not only can prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate such patients' need for the usual six months of immune suppression medicines commonly prescribed to prevent severe forms of this immune response.
Although two RNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates elicited similar, dose-dependent neutralizing antibody titers in both younger and older adults, a recent study by researchers from the U.S. and Germany has shown that BNT162b2 is associated with less systemic reactogenicity in elderly individuals – supporting its selection for further phase 2/3 clinical trials. The study is currently available on medRxiv* preprint server.
› Verified 3 days ago
Muhammad Aamer Zaman Khan, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 801 E 6th St, Ste 302, Panama City, FL 32401 Phone: 850-770-3030 Fax: 850-770-3035 | |
Dr. George Antony Barrio, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2507 Harrison Ave Ste 207, Panama City, FL 32405 Phone: 850-770-3030 Fax: 850-770-3024 | |
Dr. Royce Paul Gray, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1940 Harrison Ave, Panama City, FL 32405 Phone: 850-763-0017 Fax: 850-532-6454 | |
Justin Chou, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1940 Harrison Ave, Panama City, FL 32405 Phone: 850-763-0017 Fax: 850-692-5862 | |
Mrs. Diana F Melazzo, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1940 Harrison Ave, Panama City, FL 32405 Phone: 850-763-0017 Fax: 850-532-6454 | |
Sana Javed-ebeid, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 801 E 6th St Ste 602, Panama City, FL 32401 Phone: 850-770-3030 Fax: 850-770-3024 | |
Mr. Achraf Makki, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2202 State Ave Ste 201, Panama City, FL 32405 Phone: 850-785-0029 Fax: 850-785-7600 |